Kashiwagi, S., Yashiro, M., Takashima, T., Aomatsu, N., Ikeda, K., Ogawa, Y., . . . Hirakawa, K. (2011). Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: Usefulness of prognostic markers E-cadherin and Ki67. BioMed Central.

Kashiwagi, Shinichiro, Masakazu Yashiro, Tsutomu Takashima, Naoki Aomatsu, Katsumi Ikeda, Yoshinari Ogawa, Tetsuro Ishikawa, et Kosei Hirakawa. Advantages of Adjuvant Chemotherapy for Patients With Triple-negative Breast Cancer At Stage II: Usefulness of Prognostic Markers E-cadherin and Ki67. BioMed Central, 2011.

Kashiwagi, Shinichiro, et al. Advantages of Adjuvant Chemotherapy for Patients With Triple-negative Breast Cancer At Stage II: Usefulness of Prognostic Markers E-cadherin and Ki67. BioMed Central, 2011.